Cyclic adenosine monophosphate (CAMP) is an important modulator of platelet responses t o agonists. Cyclic nucleotide phosphodiesterase (PDE) controls intracellular cAMP concentrations by hydrolyzing it t o AMP. The major PDE activity in platelets is PDE3A (cyclic guanosine monophosphate [cGMPl-inhibited PDE). To obtain structural information on platelet PDEBA, we cloned the enzyme cDNA from a human erythroleukemia cell (HEL) library since the cell line expresses many platelet proteins. This clone consists of 87% of the full-length human myocardial PDE3A cDNA, spanning from nucleotides 456 t o 4606, and is identical in sequence. The nucleotide coding for the N terminal 179 amino acid sequence (nt 1-536) as well as four other cDNAs (nt 1459-1632, n t 1765-1986, n t 2152-2538, and n t 2978-33751 obtained YCLIC ADENOSINE monophosphate (CAMP) is one of the second messengers that regulates cell proliferation,' and cellular responses to hormones and In platelets, an increase in the intracellular level of CAMP is associated with an inhibition of platelet responses to agonists, such as shape change, adhesion, aggregation, and release of granule contents7 Elevation of cAMP is a consequence of the stimulation of adenylate cyclase, the enzyme responsible for its formation from ATP. Alternatively, inhibition of the enzymes responsible for its destruction will increase the intracellular level of CAMP. The essential enzymes for the catabolism of 3',5'-cAMP to 5'AMP are cAMP phosphodiesterases (PDEs).
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The known PDEs have been expanded recently into seven gene families according to their substrate and inhibitor specificities, kinetic characteristics, tissue distribution, primary mRNA splicing species, and their responses to effectom8 Hormones, such as insulin, glucagon, and epinephrine, and autocoids, such as prostaglandins, have been reported to regulate PDE activities in different ~ystems.~-'~ Cyclic GMP has been shown to stimulate cAMP hydrolysis by some PDEs mediated by homologous noncatalytic cyclic guanosine monophosphate (cGMP)-binding domains while inhibiting o t h e r~. '~ In addition, all PDEs contain a conserved domain of approximately 250 amino acids, which contains the amino acids essential for ~atalysis.'~ At least four forms of cyclic nucleotide PDE activities have been identified in fractions of platelet extracts, namely calmodulin-dependent PDE (PDEI), CAMP-PDE whose activity is stimulated by low levels of cGMP (PDE2),I6 low K, CAMP-PDE which is inhibited by cGMP (PDE3),I7 and cGMP-specific PDE (PDE5).'* The four forms of PDEs were affected differently by various PDE inhibitors.'8-2' PDE3 is subdivided into PDE3A for cardiac, placental, and platelet PDE3 and PDE3B for fat cell PDE3.8 PDE3A is the most abundant PDE in platelets. It has a low K, for cAMP and &MP, but the kat was 10-fold lower for cGMP than CAMP, making cGMP a potent competitive inhibitor of cAMP hydrolysis.18 Similar PDE3 activity is also found in myocardial and adipose tissue,17 but whether the platelet enzyme is identical to those from other tissues has been unclear. platelet responses to stimuli is suggested by the ability of certain PDE inhibitors to inhibit platelet responses by elevating intracellular CAMP.'^.^^ In turn, an increase in cAMP feeds back to limit the increase by stimulating CAMP-dependent protein kinase, which phosphorylates PDE3 and increases its activity."." Native platelet PDE3A has a molecular weight of 110 k D , but it is sensitive to proteolysis and isolation manipulation. The PDE3A isolated from outdated platelets consists of the C-terminal half of the molecule with a molecular weight of 61 k D , which retains the catalytic activity.26 The human heart PDE3A-encoding cDNA protein, cloned by Meacci et al,I7
encodes a protein of 125 kD. The conserved region containing the catalytic domain was identified. A recombinant PDE3A truncated at the N-terminal end (amino acids 613-1108) retains the cAMP hydrolytic activity, which is sensitive to inhibition by cGMP and OPC 391 1, but not to rolipram, an inhibitor for PDE4, the CAMP-specific PDE.25 Pillai et aI2' recently reported that a deletion mutant of human cardiac PDE3A of 46 kD in size had lost the catalytic activity, and that certain sequences between amino acid 608 and 722 were also required for catalytic activity. The precise limits of the catalytic region are not clear.
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For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From tured by glyoxal at 50°C for 60 minutes and separated by electrophoresis at I 0 0 volts at 4°C for 2.5 hours in 10 mmol/L sodium phosphate buffer, pH 6.5, in a 1% agarose gel." RNAs were then transferred from the gel to a Duralon membrane (Strategene, La Jolla. CA) by 10X SSC ( I X SSC = 0.3 mol/L NaCI, 0.015 mol/L sodium citrate) and hybridized to "P-labeled probes at 60°C overnight after baking at 80°C for 60 minutes. The blotted membrane was then washed. as below, and exposed to Kodak XAR-5 film for 7 days. The lane containing the RNA standards 0.24 to 9.5 kb (Life Technologies. Gaithersburg, MD) was excised from the gel before transfer and stained with ethidium bromide (20 pglmL in 10 mmol/L sodium phosphate buffer). All solutions were pretreated with diethylpyrocarbonate (Sigma, St Louis. MO) and autoclaved to inactivate RNase. All glassware was treated with I N NaOH before use.
Probe Inheling. PCR probes were purified by spin-bind column (FMC. Rockland, ME) before they were labeled with "P by the random-priming method.'" The labeled probes were purified by Elutip-D (Scheicher and Schnell, Keene. NH) and denatured at 95°C for 10 minutes before being added to the hybridization mix. The labeled probe was used for library screening and Northern blotting.
Hybridi.xtion. The membranes were prehybridized for 2 hours and hybridized overnight at 60°C in 5X Denhardt's solution. The membranes were then washed in 2 x SSC." Kodak XAR-5 film was exposed to the blotted membranes for 7 days at -30°C with intensifying screens.
RNA isolatior? from platelets. One unit of fresh citrated human blood collected from a donor after written informed consent was centrifuged at 1.000 rpm for 20 minutes. The platelet-rich plasma was pooled and spun at 2,400 rpm for 20 minutes to pellet the platelets. Total RNA was isolated from the platelet by the Chomcynski and Sacchi method." One unit of blood yielded approximately 300 to 500 pg of total RNA. Total RNA was used for reverse transcription-polymerase chain reaction (RT-PCR) studies.
RT-PCR. Total RNA was treated with RNase-free DNase before use. First-strand cDNA was synthesized with random primer pd(N), (Pharmacia, Piscataway, NJ) and 2 yg of total RNA by AMV reverse transcriptase (cDNA cycle kit; Invitrogen, San Diego, CA) at 42°C for 30 minutes. A higher temperature of 48°C plus another addition and incubation of AMV reverse transcriptase was needed to transcribe the region of nt 1-536. Reaction buffer was supplied with the enzyme. One-fifth (S yL) of the reaction product was used for PCR in a thermal cycler (Perkin Elmer Cetus, Nonvalk, CT). The program used was: 30 cycles of denaturation ( I minute at 94°C). annealing ( I minute at 57°C) and extension (4 minutes at 72°C). followed by a final extension at 72°C for 7 minutes after the last cycle. The final volume for PCR was 100 pL including 10 yL of 10X buffer (500 mmol/L KCI, 1 0 0 mmol/L Tris-HCI, pH 9 at 25°C. 1% Triton X-I W), 5 pL of 25 mmol/L MgCI', 5 pL of 20 mmol/L primer pairs.
16 pL of 1.25 mmol/L dATP. dCTP, dGTP, and dTTP. 10 pL of bovine serum albumin (1 mglmL), 2.5 U of Taq DNA polymerase (Perkin-Elmer Cetus). The PCR products were analyzed by 2% NuSieve agarose gel ( l %-NuSieve agarose + l % regular agarose) (FMC. Rockland. ME).
DNA sequencinP. The cDNA insert was excised from recombi- Library screening. cDNA probes were synthesized by the PCR method using oligonucleotides derived from the human myocardial PDE cDNA sequence" that were homologous to the platelet peptide sequence (pde I : 5'-ACAGGGTGATGAAGAGGCCAGCCTT-3' and pde 5: 5'-TGGTCTGGCTTTTGGGTT-3'). The template used was the total phage DNA prepared from the hgtll HEL cDNA libraries.
Yeasr and bacterial strains. Saccharomyces cerevisiae strain GL62 (MATa leu2 ura3-52 adel his3 trpl lys2-208 pdel ::LEU 2 pde2::URA3 pep 4::HIS3),"." which is deficient in yeast PDEl and PDE2 and aspartyl protease, was used as the host. Yeast vector pl38NB" was used for expression. cDNA was inserted at multiple cloning sites Xho I and BgI 11. Expression is controlled by the copperinducible CUP1 promoter. All plasmids were propagated in bacterial strain XLI-Blue MRF' (Strategene, La Jolla, CA) and GM 2163 when the restriction enzyme BsaB 1 was used (New England Biolabs, Beverly, MA).
Yeas? growth conditions. The media for yeast growth (yeast extract, peptone, and dextrose, YEPD) and synthetic complete minus tryptophan (SC-Trp) were prepared as previously de~cribed.'~ Yeast transformations were performed using the lithium acetate method."
Protein concentration determinarion. Protein concentrations in cell extracts were determined by the Coomassie Plus Protein assay reagent (Pierce, Rockford, IL). Ten microliters of cell extracts or diluents was mixed with 200 pL of assay reagent and absorbance was measured at 595 nm by Microplate Reader (Bio-Tek, Winooski, VT). Bovine serum albumin dilutions of 0 to 1 m g h L were used as standards.
Preparation of cell extracts for PDE activity assay. Recombinant yeast cells were grown in SC-Trp medium to A, nm = 0.6. CuSO, (final concentration = 150 pmol/L) was added to induce expression. After 4 hours, the cells were harvested, washed once in sterile water, and lysed at 4°C in lysis buffer with 0. 45 In vitro PDE activio assay. The enzymatic activity was assayed in 100 pL final reaction volume containing 50 mmoK Tris-HCI, pH 7.5, 20 mmol/L MgClz, 1.0 mg/mL BSA, and 1 pmol/L 'H-CAMP (50,000 cpdassay) at 24°C for 15 minutes. The reactions were stopped with 0.2 mL of 0.2 moVL ZnSO, and 0.2 mL of 0.2 mol/L Ba(OH)*. The samples were vortexed and spun at 12,000g for 3 minutes. The supernatants were added to scintillation cocktail and counted. The labeled product of the reaction, 'H-S'AMP, was precipitated by BaS04, and unreacted 'H-CAMP in the supernatant was measured."
Immunoblot analyses. Sample buffer and prestained protein markers were obtained from New England BioLabs (Beverly, MA). Ten microliters of each sample plus 5 pL of sample buffer was loaded onto a 5% stacking to 12% running SDS-PAGE gel.37 Running buffer was 25 mmoVL Tris-HCI, pH 8.8, glycine 192 mmoVL, SDS 0.1 %. Proteins were transferred from the gel to a polyvinylidene difluoride (PVCF) membrane (Immobilon-P, Millipore, Bedford, MA) by Genie electroblotter (Idea, Minneapolis, MN). After blotting, the PVDF membrane was blocked with 5% milk in 1X TBST solution (50 mmoUL Tris pH 8, 150 mmoVL NaCI, 0.05% Tween-20), washed, and incubated with rabbit anti-platelet PDE3A serum ( 1 5 0 0 dilution) for 1 hour at room temperature. Immunoreactivity was detected with goat antirabbit IgG-linked alkaline phosphatase. The signal was detected by the chemiluminescent LumiPbos-530 system (Boehringer-Mannheim, Indianapolis, IN).
Subcloning of A44-Zm-I insert into pGEM vector. Agtl 1 recombinant phage 44-2m-1 was prepared by plate culture3' and the DNA was isolated by Qiagen column (Qiagen, Chattsworth, CA). The PDE3A cDNA insert was excised by EcoRI enzyme and subcloned into the EcoRI-digested, dephosphorylated pGEM3Zf(+) vector (Promega, Madison, W). The entire insert was sequenced as above and the clone was designated as pGEM-44-2m-1.
Construction of deletion mutant PDE3Al for expression in yeast. The human platelet PDE3A yeast expression plasmid PDE3AAl was constructed as follows: A BamHI-Sca I fragment (nt 743-nt 3927) was prepared from pGEM-44-2m-1 and subcloned into a Spe I digestedglenow filledlBamH1 digested pBluescript 11 SK' vector (Strategene, La Jolla, CA) to generate pBSPDE3.3. A 380-bp PCR fragment was synthesized using a forward primer, pde30, with an Xho I site just upstream of the translation start codon, which starts translation at nt 1993 (5'-CCGCCTCGAGAAAATG"TCTGGA-CAAACCAATTCTT-3') and a reverse primer, pde31, which has PDE sequences around the unique Nde I site at nt 2393 (5"CCC-CCATATGTCCATGTGTAAATCCACTGTC-3'). This PCR fragment was cleaved by Xho I and Nde I and subcloned in the Xho U Nde I sites of pBSPDE3.3 to generate pBS3031. This truncated insert starts with nt. 1993 of the PDE3A cDNA," including the rest of the coding region and 11 80 bases of the 3' untranslated region. This insert W B S recovered by Not I digestion, followed by Klenow fill-in and Xho I digestion and was ligated into the Xho VBgl I1 (Klenow filled) cloning sites of yeast plasmid p138NB." The PCR portion of PDE3AAl was sequenced to confirm that there was no mutation introduced by the PCR reaction. PDE3AAl was transfected into yeast strain GL62.33.34 Yeast transformants were picked, grown up in SC-Trp medium, induced with CuSO,, and cell extracts were assayed for PDE activity and analyzed by SDS-PAGE and Western blotting (as described above).
Construction of deletion mutants PDE3AA2, PDE3AA3, and PDE3AA4. Plasmid pBS3031 was used for the construction of other deletion mutants. To construct deletion mutant PDE3AA2, the PCR portion of pBS3031 was replaced with PCR fragment 3631, which was synthesized with primers pde36 (pde36 = 5'-CCG-CCTCGAGAAAATGGATAACCTGGACTCA-An-3') and pde3 1. Pde36 has the Xho I site and ATG codon and starts translation at nt 2035. To construct deletion mutant PDE3AA3, PCR fragment 3431 was synthesized with primers pde34 (pde34 = 5"CCGCCT-
CGAGAAAATGGAGCAGCTAAATA-C'ITGGGAAT-3) and pde3 1.
Pde34 starts translation at nt 2056. To construct deletion mutant PDE3AA4, PCR fragment 353 1 was synthesized with primers pde35 (pde35 = 5'-CCGCCTCGAGAAAATGGTGGAAAATATAGG-AAGAAAA-3) and pde31. PCR fragments were treated with Xho I and Nde I and subcloned into Xho I and Nde I digested pBSPDE3.3. Bluescript subclones were then digested with Xho I and BsaBI and ligated to an Xho I and BsaBI digested PDE3AAl yeast recombinant plasmid. All of the PCR fragments were sequenced to confirm that no mutations were introduced by PCR. The resulting deletion subclones were introduced into GL62. Yeast transformants were cultured in 10 mL SC-Trp and cell lysates were assayed for PDE activity. 1 and pde 5 as primers. This PCR fragment was subcloned into pCRScript SK(+) (Strategene, La J o b , CA) and sequenced. The sequence was identical to the published sequence of the human myocardial PDE3A
cDNA. This fragment was used to screen the three Xgtl 1 HEL cell cDNA libraries. A total of 35 positive clones were isolated from 10' clones. Clone 44-2m-1 had the longest insert, which had an EcoRI site at nt 3959. This clone is not a full-length cDNA, as is the human heart PDE3A cDNA. It is missing the first 455 nucleotides at the 5' end. This clone and five other clones begin at or near the nucleotide 456. probably due to a blockage of reverse transcription by a secondary structure at this region. Two inverted repeated sequences were identified between nt 3 10 and 363 by a computer program (DNAsis 2.0; Hitachi Software, New Bruno, CA).
The EcoRI fragment (3491 bp long) was subcloned into pGEM-3Zf(+) plasmid (Promega) and sequenced. The sequence located downstream of nt 3959 was sequenced, after PCR amplification, with phage 44-2m-l DNA as template. The cDNA sequence is shown in Fig 1. This clone consists of 2,967 nucleotides of the coding region and 1, I79 nucleotides of the 3'-untranslated region. No poly-A tail has been found, though the polyadenylation signal AATAAA is located at nucleotide 3824 according to the numbering system of Meacci et al." The N-terminal sequence was obtained by RT-PCR using HEL cell and platelet total RNA as templates. The sequence was combined with that of clone 44-2m-1 and is shown in Fig 1. The sequence is identical to the human myocardial PDE3A cDNA sequence except at three locations. First, at nucleotides 121 -122 of the heart PDE3A," CT should be read as TC. This correction in the DNA sequence was sent to us by Dr V. Manganiello. Second, at nucleotides 187-190, we found TCCG in PDE3A RT-PCR cDNA and clone 13.2 sent to us from Dr V. Manganiello, while the published heart PDE3A cDNA sequence at this position is CTGC. This substitution will change the codons CTG and CCG to TCC and GCG, and the corresponding amino acid residues from L and P to S and A. (Dr V. Manganiello has confirmed this change [personal communication, August 19951.) Third, at nucleotide 570, we found a C in our HEL cell PDE3A cDNA instead of a T in the heart PDE3 cDNA sequence. This substitution will change the codon GCT to GCC but will not change the encoded amino acid alanine. This alteration could constitute a polymorphic marker for the PDE3A locus. We did not find T + C change at nucleotide 2 190, as reported by Kasuya et al." Several other platelet cDNA, produced by RT-PCR, corresponding to regions of the mRNA, were also sequenced (underlined in Fig l) . They are identical to both the HEL cell and myocardial PDE3A cDNA sequence, suggesting that the platelet, HEL cell and myocardial PDE3A mRNAs are transcribed from the same gene. Degerman et a14" have reported the amino acid sequences of 36 platelet PDE3A peptides, which are almost identical to the amino acid sequences deduced from the PDE3A cDNA. Some differences could be due to sequencing problems. The molecular weights of the platelet and cardiac PDE3A full-length proteins determined by SDS-PAGEmestern blot analyses are 110 kD and 125 kD, r e s p e~t i v e l y . '~. '~~~~ Since most of the platelet PDE3A activity is present in the cytosolic fraction,J' while that of the myocardial PDE3A is located in the microsomal fraction. ) . Therefore, HEL cell mRNA was used to analyze PDE3A mRNA. Two PCR-amplified cDNAs were labeled with "P-dCTP and used as probes to analyze the HEL PDE3A mRNAs. One probe includes 114 bases of the conserved region of PDE3A. and another probe is S29 nucleotides upstream from the conserved region and, thus, has no significant homology to other known PDE sequences. Both probes identified two mRNAs of sizes 4.4 and 7.5 kb, respectively (Fig 2) . The relationship of these two mRNAs to each other and to the cloned HEL cell PDE3A cDNA is not clear. Clone 44-2M-1 could possibly be encoded by the 7.5-kb mRNA because it covers 4606 nucleotides of sequence and is still missing the poly-A tail. Meacci et al'' detected a cardiac PDE3A mRNA of 8.3 kb by Northern blot analysis. They found 7.3-kb and 4.5-kb PDE3A mRNAs in human colon carcinoma cell T84. Kasuya et al recently identified a 4.4-kb PDE3A mRNA as the major transcript in placenta. 45 The transcription of this placental 4.4-kb mRNA was shown by RNase protection assay to initiate from exon 3 of the same gene that encodes for the 7.5-kb mRNA. In placenta, sequences specific to the 7.5 kb mRNA were also detected by RNase protection assay, but not by Northern blot analysis. These results can be interpreted to indicate that multiple forms of PDE3A differing in the S' amino terminal may exist in the same or different tissues. Heterogeneity of mRNA has been observed in the type 1V PDE family, where more than 15 splice variants are derived by differential splicing and alternate transcription initiation from four different genes.' Our data suggest that full-length PDE3A mRNAs were once present in platelets or megakaryocytes as suggested by the presence of PDE3 sequence nt Expression and mapping of the catalytic domain. A conserved region corresponding to amino acids 736-1011 in the myocardial PDE3A was revealed when the amino acid sequence of seven different phosphodiesterases were aligned together.17 We have aligned two more PDE sequences, Rat PDE I11 (which is type IV PDE)" and Rat fat cell PDE3B5' with that reported by Meacci et all7 by DNAsis 2.0 program (Hitachi, San Bruno, CA). Three amino acids previously identified as perfectly conserved residues are reclassified as partially conserved residues: D (991), Q (1001), and F (1004). There are 26 perfectly conserved residues in the nine different phosphodiesterases. Some of them may be important for the catalytic activity.
The conserved region" has been postulated to be the catalytic domain of PDEs. The PDE3A protein isolated from outdated platelets (amino acids 660-1 141) is a cleaved product of the whole 110 kD protein, which retains full catalytic activity.26 Meacci et all7 have constructed a deletion mutant (amino acids 613 to 1108), which retains the catalytic activity. Pillai et ai2' recently presented five deletion mutants of human myocardial PDE3A, four of which retained catalytic activity. One did not have any activity (amino acids 722-1141). They proposed that the amino acid residues from 608 to 722, upstream of the conserved region, were also required for catalytic activity.
We constructed four partial PDE3A clones and expressed them in yeast system. These clones would express PDE3A peptides of calculated molecular masses 60.4, 58.7, 57.5, and 56.0 k D . In Western blot analysis, a protein of about 60 kD was detected by rabbit anti-platelet PDE3A (lanes 4-7, Fig 3) . No protein degradation was observed for these mutants. The relative amounts of PDE3 antigen present in the 10 pg of all extracts loaded were similar in all four samples. Cell extracts from PDE3AA1 have a PDE activity of 172 pmol/mg total cellular proteidmin, while that of PDE3AA2 has a PDE activity of 79 pmol/mg/min (Fig 4) . Crude platelet extract has an activity of 200 to 500 pmol/mg/min. The catalytic activity of the crude extract from PDE3AAl and PDE3AA2 mutants is comparable with that observed in platelet preparations and that of the deletion mutants reported by Pillai et al." The other two constructs, PDE3AA3, encoding for a protein of amino acid residues 686-1141, and PDE3AA4, encoding for a protein of amino acid residues 700-1 141, did not have any PDE activity, suggesting that some or all of the amino acid residues from 679 to 700 are required for the expression of a fully active catalytic domain. The recombinant PDE3A mutant proteins were purified from PDE3AAl and PDE3AA2 yeast cultures by the method of Grant and Colmanz6 using DEAE Sepharose and Blue Dextran columns (Sigma, St Louis, MO). The purified PDE3AA1 protein has a K, of 0.20 2 0.02 pmol/L, and a V,,, of 952 f 11 nmoUmidmg. The purified PDE3AA2 has a similar K, of 0.23 f 0.03 pmol/L, and the V,,, is 550 5 25 nmol/min/mg. The ICso of cGMP, milrinone, and rolipram for PDE3AA1 are 0.45, 1.5, and >l00 pmol/L, and for PDE3AA2 are 0.50, 3.0, and >l00 pmoVL, respectively. The Km and ICso are virtually identical to the platelet enzyme purified by the same method ( Table 1) . Determination of IC5,, for PDE3AA 1 is shown in Fig 5. The V,,, of PDE3AA2 is 42% lower than that of PDE3AAl. The lower V, , , may reflect less efficient catalysis by the mutant enzyme or instability of the protein during purification.
The expression of platelet PDE3A in yeast has facilitated the investigation of the structure and function relationship of the conserved region in the protein. In the conserved region, there are 26 perfectly conserved amino acids, some of which are postulated to be important for catalytic activitys2 including seven histidine residues. Metal cations such as Mg2+, Mn2+, Zn2+, and CO'+ affect the activity of phosphodiesterase. Mg2+ and Mn2+ were found to be potent for activating the enzyme.54 The mechanism by which these metal cations influence the catalytic activity has not been documented. In the conserved domain, some of the 26 perfectly conserved amino acids display a putative zinc-binding motif of HNXXH-and HDXXH--25aa-E.s5 Mutating these conserved residues could elucidate the metal binding sites and their roles in the formation of the catalytic domain.
